Pomegra
Enveric Biosciences (ENVB) hosts partnering meetings at BIO International 2026 in San Diego as lead candidate EB-003 advances toward IND submission.
- Enveric Biosciences joins roughly 20,000 attendees at the BIO International 2026 biotech convention in San Diego, June 22-25.
- Lead neuroplastogen EB-003 has cleared phototoxicity studies and entered IND-enabling GLP genotoxicity testing, with Phase 1 entry targeted.
- A cash balance of $10.3 million as of May 2026 is projected to fund operations and the planned IND filing into Q1 2027.
Lead
Enveric Biosciences, Inc. (NASDAQ: ENVB), a clinical-stage biotechnology company developing neuroplastogenic therapies for psychiatric and neurological disorders, will participate in the 2026 BIO International Convention, set to run June 22-25 at the San Diego Convention Center in California. Members of the Enveric management team will host one-on-one meetings through the BIO One-on-One Partnering platform, with registered attendees able to submit meeting requests directly through the system.Convention Backdrop
The BIO International Convention draws approximately 20,000 participants from across the life sciences, pharmaceutical, and investment sectors and features more than 130 sessions spanning 18 scientific and business focus areas. Organized by the Biotechnology Innovation Organization, the annual biotech convention functions as the industry's primary venue for partnership discussions, capital introductions, and pipeline presentations. The 2026 edition in San Diego marks one of the largest gatherings of its kind globally, bringing together emerging biotechs and established biopharma alongside strategic and financial investors.
Pipeline Momentum
Enveric arrives at the BIO International 2026 event with a sequence of recent development milestones underpinning its presence. The company's lead asset, EB-003 — a dual modulator of the 5-HT2A and 5-HT1B serotonin receptors and the first known compound engineered to selectively engage both pathways simultaneously — has generated positive preclinical phototoxicity results and advanced into IND-enabling Good Laboratory Practice genotoxicity studies. In a PTSD model, a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-administration (p < 0.05), while in vitro pharmacology indicated a low potential for cardiovascular, respiratory, or neurological adverse effects, pointing to a favorable early safety profile.
The FDA reviewed Enveric's pre-IND submission and recommended the company proceed directly to an Investigational New Drug application, streamlining the regulatory timeline. A U.S. patent granted in the second quarter of 2026 broadened intellectual property coverage across the EVM301 series, which encompasses EB-003, reinforcing the company's position in non-hallucinogenic neuroplastogenic molecule development for neuropsychiatric and addiction indications. Enveric also continues early-stage development of EB-002, an active metabolite of psilocybin under evaluation for anxiety disorders.
Financial Position
Enveric reported a Q1 2026 net loss of $1.6 million. As of May 15, 2026, the company held approximately $10.3 million in cash, a balance management considers sufficient to support the completion of remaining preclinical activities for EB-003, the planned IND filing, and overall operations into the first quarter of fiscal 2027.
Outlook
Enveric Biosciences enters the 2026 BIO International Convention with IND-enabling studies underway, a streamlined FDA regulatory path secured, and strengthened intellectual property. The San Diego partnering meetings represent a targeted opportunity to advance strategic discussions as EB-003 tracks toward Phase 1 clinical entry — the company's next material inflection point within the current cash runway.Strategy
